<dd id="rw0xn"></dd>
If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more.
IAEA-TECDOC-2057
English IAEA-TECDOC-2057 | 978-92-0-121324-2
54 pages | 20 figures | € 30.00 | Date published: 2024https://doi.org/10.61092/iaea.95h3-2ji2
INTERNATIONAL ATOMIC ENERGY AGENCY, Production and Quality Control of Actinium-225 Radiopharmaceuticals, IAEA-TECDOC-2057, IAEA, Vienna (2024), https://doi.org/10.61092/iaea.95h3-2ji2
This publication includes existing experiences, lessons learned, challenges and future developments in the production of Ac-225 radiopharmaceuticals for Targeted Alpha Therapy (TAT). This publication will be utilized by all involved professionals in the Targeted Alpha Therapy field, specifying ideal production, formulation, quality control and regulatory aspects of various Ac-225 radiopharmaceuticals. The intended audience also includes radiochemists, radiopharmacists, and medical physicists.
More Information on reusing IAEA copyright material.
Orders and requests for information may also be addressed to:
Publishing Section
International Atomic Energy Agency
Vienna International Centre
PO Box 100, A-1400 Vienna,
Austria
Tel.: +43 1 2600 22529, +43 1 2600 22530
Email: sales.publications@iaea.org
<dd id="rw0xn"></dd>
